開拓藥業有限公司*

KINTOR PHARMACEUTICAL LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 9939)

VOLUNTARY ANNOUNCEMENT

COMPLETION OF FIRST PATIENT ENROLLMENT IN LONG-TERM SAFETY PHASE III TRIAL OF KX-826 FOR TREATMENT OF AGA

This is a voluntary announcement made by Kintor Pharmaceutical Limited (the "**Company**", together with its subsidiaries, the "**Group**") to update its shareholders and potential investors on the latest business advancement of the Group.

The board (the "**Board**") of directors (the "**Directors**") is pleased to announce that the Company has initiated the long-term safety trial (the "**Long-term Safety Trial**") of KX-826, a potential first-in-class androgen receptor (AR) antagonist for the treatment of androgenetic alopecia ("**AGA**") developed by the Group, in China and has completed the first patient enrollment on 19 July 2023. The Long-term Safety Trial was approved to be conducted by China National Medical Products Administration ("**NMPA**") on 18 April 2023.

The Long-term Safety Trial is a multi-center, open-label phase III clinical trial, which involves a total of 16 clinical research centers in China, with Professor Jianzhong Zhang (張建中) of Peking University People's Hospital as the leading principal investigator (leading PI). A total of 270 male and female AGA patients will be enrolled to evaluate the long-term safety of the topical use of KX-826 for the treatment of AGA in China (treatment period of 52 weeks). The primary endpoint of the trial is the incidence of treatment emergent adverse events ("**TEAE**"). Secondary endpoints include efficacy as measured by the change in target area non-vellus hair count ("**TAHC**") from baseline and other safety indicators.

Previously, the Company has successfully completed the phase II trial for male in China, the phase II trial for female in China and the phase II trial for male in the United States for KX-826 in the treatment of AGA. In each trial, after 24-week administration, KX-826 improved hair growth and demonstrated a favorable safety profile. Most of the adverse events occurred during the study were mild, and similar to placebo, no TEAE resulting in patient withdrawal from the trial, nor death was reported. The Long-term Safety Trial will further explore the long-term safety and efficacy of KX-826 in the treatment of AGA on the basis of the safety profile and efficacy of the above mentioned trials, which will help provide more data to support the use of such medication for long-term treatment for AGA patients.

For details of the relevant announcements, please refer to the announcements of the Company dated 8 September 2021, 1 December 2022 and 11 May 2023.

Warning under Rule 18A.05 of the Listing Rules: There is no assurance that the Company will ultimately be able to successfully develop and market KX-826. Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
KINTOR PHARMACEUTICAL LIMITED
Dr. Youzhi Tong
Chairman of the Board, Executive Director and Chief Executive Officer

Hong Kong, 19 July 2023

As at the date of this announcement, the executive Directors are Dr. Youzhi Tong, Dr. Qun Lu and Dr. Xiang Ni; the non-executive Directors are Mr. Weipeng Gao, Ms. Geqi Wei and Mr. Chengwei Liu; and the independent non-executive Directors are Dr. Michael Min Xu, Mr. Wallace Wai Yim Yeung and Prof. Liang Tong.

* *For identification purpose only*